1-844-762-9522 info@rdxbioscience.com

Respiratory Pathogen Panel

The Need

Flu and other serious pulmonary infections affect 5 million people annually, killing 500,000.

Treatments vary greatly for bacterial or viral infections – Identification of the pathogen is necessary for rapid appropriate intervention, to limit the duration and severity of symptoms.

Antibiotic resistance, accelerated by the needless use of antibiotics during a viral infection, is cited by the World Health Organization as a major threat to global public health.

What is PCR?

Polymerase Chain Reaction testing (PCR) enables highly accurate and rapid identification of disease. It is a technique by which we can obtain genetic material from a virus or bacteria and force the RNA to replicate for study in the lab. Because we know the genetic markers for infectious disease, we can compare the specimen to known pathogens and identify the infection with very high confidence.

PCR vs. Conventional Testing

Conventional culture and sensitivity testing routinely requires a few days, and sometimes a week or more

RDx delivers PCR test results within 48 hours.

Molecular testing is more sensitive, more accurate, more rapid, with more information delivered.

Respiratory Pathogen Panel Targets

Viral Targets

Influenza A

Rhinovirus/Enterovirus

Adenovirus

Influenza A H1

Parainfluenza virus 1

Coronovirus HKU1

Influenza A H3

Parainfluenza virus 2

Coronavirus NL63

Influenza B

Parainfluenza virus 3

Coronovirus 229E

Respiratory Syncytial Virus A

Parainfluenza virus 4

Coronavirus OC43

Respiratory Syncytial Virus B

Human Metapneumovirus

Human Bocavirus

Bacterial Targets

Chlamydophila pneumoniae

Mycoplasma pneumoniae

Molecular testing compared to Screening for Flu

Screening cannot determine between species of flu.

Screening cannot detect other viral infections, or bacterial infections.

Screening is reasonably accurate (over 89%) if there is a large input of pathogen to test. But accuracy drops well below coin-toss odds (down to 31%) when patient infection is below the levels necessary to screen.

Screening is prone to false results due to inconsistencies in sample collection and preparation.

Due to the challenges inherent in screening, both positive and negative results should be verified by molecular testing.

About RDx BioScience

 

RDx is a full-service, high-technology laboratory. As a diagnostics-driven bioscience firm, we pioneer new strategies to guide the care for the chronically ill, and we measure our success – not in the number of tests performed – but in terms of lives improved and patients saved.
We are fast, accurate, and deliver value-based service nationally. RDx BioScience is accredited by the College of American Pathologists (CAP) as a certified, full-service medical laboratory.

Share This